Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day had annual sales of US $330 million in the United States
Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa
The products will be manufactured at the company's facility in Bengaluru
The company has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) at a manufacturing site situated at Savli, Vadodara, Gujarat, with Zero 483 observations
The inspection was a cGMP Inspection and had ended with NIL observations
Ayushman Bhav a comprehensive nationwide healthcare initiative ensures saturation coverage of healthcare schemes, reaching every village and town
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
JB Pharma reported 19% decrease in GHG intensity as compared to last year and commenced its journey of Scope 3 emissions
The products will be manufactured at the company's facility in Bengaluru
Subscribe To Our Newsletter & Stay Updated
